Guangzhou Moxi Biotechnology Co., Ltd.

Primary objective: The bioequivalence study was conducted using fenofibrate capsules (0.2 g) held by Guangzhou Moxi Biotechnology Co., Ltd. as the test preparation and fenofibrate capsules (trade name: Lipanthyl, specification: 0.2 g) held by Abbott Laboratories Limit ED as the reference preparation to compare the bioequivalence of the two preparations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of a single oral dose of the test preparation (fenofibrate capsules, T) and the reference preparation (Lipanthyl, R) in healthy adult participants in China.